These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3933709)

  • 1. Long term effects of cyclophosphamide on testicular function.
    Watson AR; Rance CP; Bain J
    Br Med J (Clin Res Ed); 1985 Nov; 291(6507):1457-60. PubMed ID: 3933709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Delayed effect of cyclophosphamide on testicular function after treatment of nephrotic syndrome in childhood].
    Bogdanović R; Cvorić A; Banićević M; Zdravković D; Nikolić V; Ognjanović M
    Srp Arh Celok Lek; 1990; 118(5-6):235-42. PubMed ID: 2127483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.
    Bogdanović R; Banićević M; Cvorić A
    Pediatr Nephrol; 1990 Sep; 4(5):451-4. PubMed ID: 2242303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of simultaneous gonadotropin-releasing hormone agonist and testosterone treatment on spermatogenesis and potential fertilizing capacity in male monkeys.
    Mann DR; Gould KG; Smith MM; Duffey T; Collins DC
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1215-24. PubMed ID: 3316265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-Tryptophan-6 analog of luteinizing hormone-releasing hormone as a protective agent against testicular damage caused by cyclophosphamide in baboons.
    Lewis RW; Dowling KJ; Schally AV
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2975-9. PubMed ID: 3157995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of spermatogenesis recovery among workers exposed to 1,2-dibromo-3-chloropropane.
    Olsen GW; Lanham JM; Bodner KM; Hylton DB; Bond GG
    J Occup Med; 1990 Oct; 32(10):979-84. PubMed ID: 2124613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.
    Ward JA; Robinson J; Furr BJ; Shalet SM; Morris ID
    Cancer Res; 1990 Feb; 50(3):568-74. PubMed ID: 2137024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadal function, testicular histology, and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome.
    Etteldorf JN; West CD; Pitcock JA; Williams DL
    J Pediatr; 1976 Feb; 88(2):206-12. PubMed ID: 1249681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclical combination chemotherapy and gonadal function. Retrospective study in males.
    Chapman RM; Sutcliffe SB; Rees LH; Edwards CR; Malpas JS
    Lancet; 1979 Feb; 1(8111):285-9. PubMed ID: 84944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of testosterone to prevent cyclophosphamide-induced azoospermia.
    Masala A; Faedda R; Alagna S; Satta A; Chiarelli G; Rovasio PP; Ivaldi R; Taras MS; Lai E; Bartoli E
    Ann Intern Med; 1997 Feb; 126(4):292-5. PubMed ID: 9036801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small testicles with impaired production of sperm in adult male survivors of childhood malignancies.
    Siimes MA; Rautonen J
    Cancer; 1990 Mar; 65(6):1303-6. PubMed ID: 2106385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.